Conditional survival in patients with chronic myeloid leukemia in chronic phase in the era of tyrosine kinase inhibitors

Cancer

Volumn 122, Issue 2, 2016, Pages 238-248

  Sasaki, Koji ^a,b   Kantarjian, Hagop M ^a   Jain, Preetesh ^a   Jabbour, Elias J ^a   Ravandi, Farhad ^a   Konopleva, Marina ^a   Borthakur, Gautam ^a   Takahashi, Koichi ^a   Pemmaraju, Naveen ^a   Daver, Naval ^a   Pierce, Sherry A ^a   O'Brien, Susan M ^a   Cortes, Jorge E ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b TOKYO MEDICAL AND DENTAL UNIVERSITY   (Japan)

Author keywords

chronic myeloid leukemia; conditional survival; response; tyrosine kinase inhibitors

Indexed keywords

DASATINIB; IMATINIB; PROTEIN KINASE INHIBITOR;

ADOLESCENT; ADULT; AGE; AGED; ANALYSIS OF VARIANCE; DISEASE FREE SURVIVAL; DOSE RESPONSE; DRUG ADMINISTRATION; FEMALE; HUMAN; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE; LEUKEMIA, MYELOID, CHRONIC-PHASE; MALE; MIDDLE AGED; MORTALITY; MULTIVARIATE ANALYSIS; PREDICTIVE VALUE; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL (TOPIC); SEVERITY OF ILLNESS INDEX; SEX DIFFERENCE; SURVIVAL ANALYSIS; TREATMENT OUTCOME; VERY ELDERLY; YOUNG ADULT;

ADOLESCENT; ADULT; AGE FACTORS; AGED; AGED, 80 AND OVER; ANALYSIS OF VARIANCE; DASATINIB; DISEASE-FREE SURVIVAL; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; IMATINIB MESYLATE; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE; LEUKEMIA, MYELOID, CHRONIC-PHASE; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; PREDICTIVE VALUE OF TESTS; PROSPECTIVE STUDIES; PROTEIN KINASE INHIBITORS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SEVERITY OF ILLNESS INDEX; SEX FACTORS; SURVIVAL ANALYSIS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84954076925     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.29745     Document Type: Article

References (18)

1. Kantarjian HM, Shah NP, Cortes JE, et al., Dasatinib or imatinib in newly diagnosed chronic-phase chronic myeloid leukemia: 2-year follow-up from a randomized phase 3 trial (DASISION). Blood. 2012; 119: 1123-1129.
2. Kantarjian H, Pasquini R, Levy V, et al., Dasatinib or high-dose imatinib for chronic-phase chronic myeloid leukemia resistant to imatinib at a dose of 400 to 600 milligrams daily: 2-year follow-up of a randomized phase 2 study (START-R). Cancer. 2009; 115: 4136-4147.
3. Kantarjian H, Shah NP, Hochhaus A, et al., Dasatinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med. 2010; 362: 2260-2270.
4. Cortes JE, Jones D, O'Brien S, et al., Results of dasatinib therapy in patients with early chronic-phase chronic myeloid leukemia. J Clin Oncol. 2010; 28: 398-404.
5. Kantarjian HM, Giles FJ, Bhalla KN, et al., Nilotinib is effective in patients with chronic myeloid leukemia in chronic phase after imatinib resistance or intolerance: 24-month follow-up results. Blood. 2011; 117: 1141-1145.
6. Jain P, Kantarjian H, Alattar ML, et al., Long-term molecular and cytogenetic response and survival outcomes with imatinib 400 mg, imatinib 800 mg, dasatinib, and nilotinib in patients with chronic-phase chronic myeloid leukaemia: retrospective analysis of patient data from 5 clinical trials. Lancet Haematol. 2015; 2: e118-e128.
7. Sasaki K, Strom SS, O'Brien S, et al., Relative survival in patients with chronic-phase chronic myeloid leukaemia in the tyrosine-kinase inhibitor era: analysis of patient data from 6 prospective clinical trials. Lancet Haematol. 2015; 2: e186-e193.
8. Quintas-Cardama A, Choi S, Kantarjian H, Jabbour E, Huang X, Cortes J,. Predicting outcomes in patients with chronic myeloid leukemia at any time during tyrosine kinase inhibitor therapy. Clin Lymphoma Myeloma Leuk. 2014; 14: 327-334.e8.
9. Brenner H, Gondos A, Pulte D,. Recent trends in long-term survival of patients with chronic myelocytic leukemia: disclosing the impact of advances in therapy on the population level. Haematologica. 2008; 93: 1544-1549.
10. Janssen-Heijnen ML, Gondos A, Bray F, et al., Clinical relevance of conditional survival of cancer patients in Europe: age-specific analyses of 13 cancers. J Clin Oncol. 2010; 28: 2520-2528.
11. Cortes JE, Jones D, O'Brien S, et al., Nilotinib as front-line treatment for patients with chronic myeloid leukemia in early chronic phase. J Clin Oncol. 2010; 28: 392-397.
12. Quintas-Cardama A, Kantarjian H, Jones D, et al., Delayed achievement of cytogenetic and molecular response is associated with increased risk of progression among patients with chronic myeloid leukemia in early chronic phase receiving high-dose or standard-dose imatinib therapy. Blood. 2009; 113: 6315-6321.
13. Baccarani M, Deininger MW, Rosti G, et al., European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013. Blood. 2013; 122: 872-884.
14. Kaplan EL, Meier P,. Nonparametric estimation from incomplete observations. J Am Stat Assoc. 1958; 53: 457-481.
15. Skuladottir H, Olsen JH,. Conditional survival of patients with the 4 major histologic subgroups of lung cancer in Denmark. J Clin Oncol. 2003; 21: 3035-3040.
16. Cox DR, Oakes D,. Analysis of Survival Data. London: Chapman & Hall; 1984.
17. Kantarjian HM, Cortes J, Guilhot F, Hochhaus A, Baccarani M, Lokey L,. Diagnosis and management of chronic myeloid leukemia: a survey of American and European practice patterns. Cancer. 2007; 109: 1365-1375.
18. Arias E,. United States life tables, 2010. Natl Vital Stat Rep. 2014; 63: 1-63.